Geneos Wealth Management’s Frontline FRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-200
Closed -$1K 2924
2020
Q3
$1K Hold
200
﹤0.01% 2516
2020
Q2
$1K Hold
200
﹤0.01% 2459
2020
Q1
$1K Buy
+200
New +$1.86K ﹤0.01% 2369
2018
Q2
Sell
-2,604
Closed -$11K 2284
2018
Q1
$11K Sell
2,604
-40
-2% -$179 ﹤0.01% 1605
2017
Q4
$12K Sell
2,644
-60
-2% -$335 ﹤0.01% 1563
2017
Q3
$16K Hold
2,704
﹤0.01% 1403
2017
Q2
$15K Buy
2,704
+48
+2% +$295 ﹤0.01% 1379
2017
Q1
$17K Buy
2,656
+36
+1% +$251 ﹤0.01% 1294
2016
Q4
$18K Buy
2,620
+4
+0.2% +$30 ﹤0.01% 1229
2016
Q3
$18K Buy
2,616
+62
+2% +$479 ﹤0.01% 1161
2016
Q2
$20K Buy
2,554
+67
+3% +$551 ﹤0.01% 1113
2016
Q1
$20K Buy
+2,487
New +$24K ﹤0.01% 1085

Other funds holding FRO

Geneos Wealth Management's FRO Position: Q4 2020 in Review

Geneos Wealth Management sold out of Frontline (FRO) in Q4 2020, closing a stake of 200 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in FRO in Q1 2016 and held it in 12 quarters. The position peaked at $20K in Q2 2016. 126 funds tracked by Wall St. Rank hold FRO as of Q4 2020.

  • Geneos Wealth Management reported no remaining Frontline position as of Q4 2020 after selling out during the quarter.
  • Geneos Wealth Management sold 200 Frontline shares in Q4 2020, an estimated $1K.
  • Geneos Wealth Management first reported a position in Frontline in Q1 2016 and held it in 12 quarters.
  • Geneos Wealth Management's Frontline position peaked at $20K in Q2 2016.
  • 126 funds tracked by Wall St. Rank held Frontline as of Q4 2020.

Based on Geneos Wealth Management's 13F filing for Q4 2020, filed 19 May 2021.